VACS Antiviral Workgroup

Slides:

Advertisements

Similar presentations

Adherence to HCV Therapy: Relation with Virologic Outcomes and Changes in Adherence Over Time Vincent Lo Re, MD, MSCE V. Teal, R. Localio, V. Amorosa,

Advertisements

1 Severe morbidity among HIV- infected patients : a comparison between a Brazilian and a French clinic based observational cohort FIOCRUZ: Prof B Grinsztejn.

Increased Risk of Hepatic Decompensation in HIV/HCV-Coinfected Versus HCV-Monoinfected Patients Despite ART Vincent Lo Re, MD, MSCE J Tate, MJ Kallan,

Washington D.C., USA, July 2012www.aids2012.org Access to HCV treatment for people with HIV/HCV Professor Gregory Dore Viral Hepatitis Clinical Research.

Biomarkers of Inflammation, Coagulation and Monocyte Activation Are Strongly Associated with the VACS Index among Veterans on cART Amy Justice* 1,2, Matthew.

Capture of acute myocardial infarctions occurring at non-VA hospitals by outpatient, VA Healthcare System ICD-9 codes CONCLUSIONS 1.NVH records can be.

Division of Infectious Diseases Division of Infectious Diseases Department of Medicine  Gary Simon  David Parenti  Carmen Tuazon  Afsoon Roberts 

Morbidity Monitoring Project Data for Resource Planning and Evaluation A.D. McNaghten Centers for Disease Control and Prevention.

Patient Empowerment Impacts Medication Adherence among HIV-Positive Patients in the Veteran’s Health Administration Tan Pham 1,2,3, Kristin Mattocks 1,2,

ADAP Solutions for the future Glen Pietrandoni, R.Ph., AAHIVP, Sr Director, Virology Adam Reno, Sr. Strategic Account Manager, State Governments ©2013.

Generously supported by the Robert Wood Johnson Foundation Clinical Scholars Program, Department of Veteran Affairs, and National Institutes of Health,

November 5, 2014 Matthew Tuck, MD Hospitalist, Veterans Affairs Medical Center Assistant Professor of Medicine, George Washington University.

The Impact of Integrated HIV Care on Patient Health Outcomes Tuyen Hoang, PhD Matthew B. Goetz, MD, Elizabeth Yano, PhD, Barbara Rossman, PhD, Henry D.

Veterans Aging Cohort Study (VACS)

1/11/01 Pediatric trials for ARV experienced children Coleen K. Cunningham Epidemiology of treatment experience in pediatrics How does the smaller number.

HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.

Harry Lampiris, MD, Moderator Chief, ID Section, Medical Service, SFVAMC Professor of Clinical Medicine, UCSF.

Where Are We on the Path to Elimination of Chronic Hepatitis C?

Abstract MOAB0301 Hepatitis C Care Cascade for People Living With HIV in the Country of Georgia Nikoloz Chkhartishvili1, A. Abutidze1, N. Bolokadze1, O.

Veterans Aging Cohort Study (VACS)

Treatment Outcomes for Chronic Hepatitis C Infection with Direct Acting Antivirals among Inmates in Federal Corrections Smith JM, Boudreau H, Kom E, Tremblay.

VACS Cancer Core Robert Dubrow, PhD, MD Founding Director

Hepatitis C Incidence and Prevalence in the U.S.

Eradication of HCV induced by DAAs

Alcohol, Other Drugs, and Health: Current Evidence March–April 2017

VACS Alcohol and Behavior Change Core

HSR Core Co-Chairs: Emily Wang, MD Kathleen McGinnis, DrPH

VACS Polypharmacy Workgroup

Janet P. Tate, MPH, ScD Co-Director

HIV/HCV Co-Infection Case

Chronic Hepatitis C Virus Infection

VACS Opioids Workgroup

Expanding the Universe of Viral Hepatitis Treaters

Maria Rodriguez-Barradas

VACS Cardiovascular Disease Core

VACS Uniformed Services Workgroup

More Than Treatment.

VACS Endocrine and Bone Workgroup

What Does the Primary Care Physician Need to Know About Chronic Hepatitis C?

Hepatitis C in the HIV-infected patient

Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes:

Phase 3 Treatment Naïve and Treatment Experienced HIV Coinfection

Division of Viral Hepatitis, CDC

2018 Postgraduate Research Symposium: Exploring opportunities

VACS Cardiovascular Disease Core

A Guideline-Based Approach to HCV Care

RL Cook, KA McGinnis, DA Fiellin, JH Samet, JL Goulet, S Crystal

Quality of HIV Care and Mortality in HIV-Infected Patients Who Use Drugs and Alcohol PT Korthuis, KL Kraemer, KA McGinnis, M Skanderson, AJ Gordon, AC.

Pneumococcal Polysaccharide (PV) Vaccine Failures among HIV-infected Veterans Compared to Non-HIV-infected controls. Maria C. Rodriguez-Barradas, MD.

Cholesterol Management in HIV-infected and Uninfected Patients: The Veterans Aging Cohort Study Leaf, DA, Goulet J, Goetz MB, Oursler KA, Gilbert C, Frieberg.

Impact of Hepatitis C, HIV, or Both on Survival in Veterans in Care Before and After the Introduction of HAART (1996) SL Fultz, MD, MPH CH Chang, PhD AA.

Amy C. Justice, MD, PhD For the VACS Project Team

VACS Scientific Meeting October 15, 2008 Joseph K. Lim, M.D.

Update on the VACS New ART Initiator Protocol and Substudy

Depression Treatment in HIV-infected and Uninfected Veterans: Do Rates Vary by HIV Status? Kristen Sueoka YSM IV.

Quality of HIV Care for Veterans with Unhealthy Alcohol Use

Farah Kidwai-Khan, Janet Tate, Cynthia Brandt, Amy Justice

Veterans Aging Cohort Study Site Evaluations

The Power of Propensity Score Matching to Remove Confounding by Indication: Statins and Acute Myocardial Infarction among HIV Infected and Uninfected.

Patterns, predictors, and consequences of non-medical use prescription opioids in the Veterans Aging Cohort Study Brandon DL Marshall, PhD Manning Assistant.

Shawn L Fultz, MD MPH VACS Scientific Meeting, Feb 2004

Hashem B. El-Serag, Thomas P

Jeffrey P. Anderson Combination Antiretroviral Therapy and Hepatic Decompensation in HIV/HCV Coinfected Veterans JEFFREY P. ANDERSON.

REAL-WORLD SAFETY, EFFECTIVENESS, AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION TREATED WITH GLECAPREVIR/PIBRENTASVIR:

Update on the VACS HIV CVD Substudy and Preliminary Analyses

Biostatistics Core Members Joyce Chang Kirsha Gordon Joseph Goulet

Melissa Herrin, Jan Tate ScD, MPH & Amy Justice, MD, PhD

VACS Scientific Meeting 2016

VACS Statins Workgroup

Presentation transcript:

VACS Antiviral Workgroup Neel Gandhi, MD Current Co-Director Members Scott Braithwaite Sheldon Brown Emily Cartwright Kathy DeSilva Jennifer Edelman Cynthia Gibert Matthew Goetz Vincent Marconi David Rimland Maria Rodriguez-Barradas Christopher Rentsch, Current Co-Director Janet Tate, ScD Founding Co-Director

Past work Current work Summary of Activities Validation of an algorithm to identify antiretroviral-naïve status at time of entry into a large, observational cohort of HIV-infected patients. Pharmacoepidemiol Drug Saf. 2013 Sep;22(9):1019-25. Impact of Defined Clinical Population and Missing Data on Temporal Trends in HIV Viral Load Estimation within a Healthcare System. HIV Med. 2015 Feb 17. Current work Hepatitis C Treatment Validation Determine ability of pharmacy data to identify whether patient has received DAA HCV treatment Compare pharmacy data-derived HCV treatment regimen with medical record review at Atlanta, Houston, Washington, New York and Los Angeles >95% agreement Hepatitis C treatment receipt and outcomes in DAA era